Editorial: With a little help from my friends
Perspective: Safety of osteoanabolic therapy: A decade of experience
Original Article: The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years
Commentary: An ELIXIR for bone loss?
Original Article: Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss